Failure-mode evidence depth
Coverage meters, not risk scores. Open the linked section to read direction.Stack
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
How stable is the peptide in biological matrices or protease systems?
What safety, toxicity, or tolerability evidence is attached?
Not availablePolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
3 Ro5 violations · MW 1,140.25 Da
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 100 % | Comparable | PepTherDia curated product PK field | Route: IV · 68 · Anidulafungin · exact product name match · exact or normalized match | Open |
| 2 | 2-7 % | Comparable | PepTherDia curated product PK field | Route: ORAL · 68 · Anidulafungin · exact product name match · exact or normalized match | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 92500 ng*h/mL | Comparable | AUC (0 to infinity) in human plasma at 100 mg, iv by LC-MS/MS analysis · human · plasma | Route: iv · area under curve · AUC· AUC (0 to infinity) in human plasma at 100 mg, iv by LC-MS/MS ana... | Open |
| 2 | 101000 ng*h/mL | Comparable | AUC (0 to t) in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions · human | Route: iv · area under curve · AUC· AUC (0 to t) in healthy human at 200 mg, iv on day 1 as 200 mins... | Open |
| 3 | 98000 ng*h/mL | Comparable | AUC (0 to t) in human plasma at 100 mg, iv by LC-MS/MS analysis · human · plasma | Route: iv · area under curve · AUC· AUC (0 to t) in human plasma at 100 mg, iv by LC-MS/MS analysis ·... | Open |
| 4 | 55.2 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin patient table6 auc ss mean 100 50 ·... | Open |
| 5 | 110.3 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin patient table6 auc ss mean 200 100 ·... | Open |
| 6 | 41.1 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table7 auc ss mean · Table... | Open |
| 7 | 56.2 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table7 auc ss mean · Table... | Open |
| 8 | 96.1 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table7 auc ss mean · Table... | Open |
| 9 | 102.9 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table7 auc ss mean · Table... | Open |
| 10 | 69.9 mg*h/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table8 auc ss mean · Table... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 5788.2 nM | Comparable | Cmax in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions · human | Route: iv · max concentration · Cmax· Cmax in healthy human at 200 mg, iv on day 1 as 200 mins infusi... | Open |
| 2 | 9647.01 nM | Comparable | Cmax in human at 100 mg/day · human | max concentration · Cmax· Cmax in human at 100 mg/day · Exact ChEMBL pref name ANIDULAFUN... | Open |
| 3 | 3183.51 nM | Comparable | Cmax in human plasma at 100 mg, iv by LC-MS/MS analysis · human · plasma | Route: iv · max concentration · Cmax· Cmax in human plasma at 100 mg, iv by LC-MS/MS analysis · Exact... | Open |
| 4 | 4.2 mg/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin patient table6 cmax ss mean 100 50 ·... | Open |
| 5 | 7.2 mg/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin patient table6 cmax ss mean 200 100... | Open |
| 6 | 3.32 mg/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table7 cmax ss mean · Tabl... | Open |
| 7 | 4.35 mg/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table7 cmax ss mean · Tabl... | Open |
| 8 | 7.57 mg/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table7 cmax ss mean · Tabl... | Open |
| 9 | 6.88 mg/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table7 cmax ss mean · Tabl... | Open |
| 10 | 6.7 mg/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin pediatric table8 cmax ss mean · Tabl... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1.9 hr 6840 seconds | Comparable | Tmax in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions · human | Route: iv · time to max concentration · Tmax· Tmax in healthy human at 200 mg, iv on day 1 as 200 min... | Open |
| 2 | 1.78 hr 6408 seconds | Comparable | Tmax in human plasma at 100 mg, iv by LC-MS/MS analysis · human · plasma | Route: iv · time to max concentration · Tmax· Tmax in human plasma at 100 mg, iv by LC-MS/MS analysis... | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 30-50 L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · volume of distribution hyphen range · Distribution... | Open |
| 2 | 30.8 L | Comparable | Volume of distribution at steady state in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions · human | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in healthy human at... | Open |
| 3 | 0.57 L/kg | Comparable | Volume of distribution at steady state in human after iv administration · human | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in human after iv a... | Open |
| 4 | 32.6 L | Comparable | Volume of distribution at steady state in human plasma at 100 mg, iv by LC-MS/MS analysis · human · plasma | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in human plasma at... | Open |
| 5 | 2.2 L/kg | Comparable | Volume of distribution in F344 rat at 5 mg/kg, iv administered as single bolus dose · rat | Route: iv · volume of distribution · Vd· Volume of distribution in F344 rat at 5 mg/kg, iv administer... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 84 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: IV · 68 · Anidulafungin · exact product name match · exact or normalized match | Open |
| 2 | 99 % | Comparable | Plasma protein binding in patient with serious fungal disease by equilibrium dialysis · human · plasma | plasma protein binding · PPB· Plasma protein binding in patient with serious fungal disea... | Open |
| 3 | 84 % | Comparable | Plasma protein binding in patient with serious fungal disease by ultrafiltration · human · plasma | plasma protein binding · PPB· Plasma protein binding in patient with serious fungal disea... | Open |
| 4 | 80 % | Comparable | Protein binding in Candida albicans K-1 infected neutropenic ICR/Swiss mouse serum after 30 mins by arithmetic dilution method · mouse · serum | plasma protein binding · PPB· Protein binding in Candida albicans K-1 infected neutropeni... | Open |
| 5 | 99 % | Comparable | Protein binding in human serum by equilibrium dialysis · human · serum | plasma protein binding · PPB· Protein binding in human serum by equilibrium dialysis · Ex... | Open |
| 6 | 99 % | Comparable | Protein binding in mouse serum by equilibrium dialysis · mouse · serum | plasma protein binding · PPB· Protein binding in mouse serum by equilibrium dialysis · Ex... | Open |
| 7 | > 99 % | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Anidulafungin· 12.3 Pharmacokinetics · plasma binding extensively bound parenthetical per... | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.21 mL/min/kg | Comparable | Clearance in human after iv administration · human | Route: iv · clearance · CL· Clearance in human after iv administration · Exact ChEMBL pref name ANIDU... | Open |
| 2 | 0.913 L/h | Comparable | Clearance in human plasma at 100 mg, iv by LC-MS/MS analysis · human · plasma | Route: iv · clearance · CL· Clearance in human plasma at 100 mg, iv by LC-MS/MS analysis · Exact ChEM... | Open |
| 3 | 1 L/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin patient table6 clearance mean · Tabl... | Open |
| 4 | 0.84 L/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin table5 clearance regimen 1 · Table 5... | Open |
| 5 | 0.94 L/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin table5 clearance regimen 2 · Table 5... | Open |
| 6 | 0.78 L/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · anidulafungin table5 clearance regimen 3 · Table 5... | Open |
| 7 | ~ 1 L/h | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Anidulafungin· 12.3 Pharmacokinetics · clearance single · time curve CL = clearance t 1/2... | Open |
| 8 | 14 mL/min/kg | Comparable | Total body clearance in F344 rat at 5 mg/kg, iv administered as single bolus dose · rat | Route: iv · clearance · CL· Total body clearance in F344 rat at 5 mg/kg, iv administered as single bo... | Open |
| 9 | 17.1 L/h | Comparable | Total body clearance in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions · human | Route: iv · clearance · CL· Total body clearance in healthy human at 200 mg, iv on day 1 as 200 mins... | Open |
| 10 | Observation The population pharmacokinetic analysis showed that median clearance differed slightly between the elderly group (patients ≥65, median CL=1.07 L/h) and the non-elderly group (patients <65, median CL=1.22 L/h) and the range of clearance was similar. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Anidulafungin· 12.3 Pharmacokinetics · anidulafungin elderly clearance similarity text ·... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
The identity reference does not expose a sequence string.
No reported sequence notation is available in the current identity references.
No sequence representation
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference link | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Plasma Protein Binding +1 more | No reported alias | 0 identity 39 evidence |
PubMed 18070979 | DistributionExposure Area Under Curve, Max Concentration, Plasma Protein Binding | No reported alias | 0 identity 7 evidence |
PubMed 19029327 | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Time To Max Concentration +1 more | No reported alias | 0 identity 6 evidence |
PubMed 19770284 | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Time To Max Concentration +1 more | No reported alias | 0 identity 5 evidence |
Reference link | DistributionExposure Bioavailability, Plasma Protein Binding | No reported alias | 1 identity 3 evidence |
PubMed 18443124 | DistributionPersistence Clearance, Volume Of Distribution | No reported alias | 0 identity 2 evidence |
PubMed 18426954 | DistributionPersistence Clearance, Volume Of Distribution | No reported alias | 0 identity 2 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0029896' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.